Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer

• Main Authors: Meng Wu (Author), Jingyi Cui (Author), Huimin Hou (Author), Ying Li (Author), Shengjie Liu (Author), Li Wan (Author), Lili Zhang (Author), Wei Huang (Author), Gaoyuan Sun (Author), Jingchao Liu (Author), Pengfei Jin (Author), Shunmin He (Author), Ming Liu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: The inactivation of tumor-suppressor p53 plays an important role in second generation anti-androgens (SGAs) drug resistance and neuroendocrine differentiation in castration-resistant prostate cancer (CRPC). The reactivation of p53 by blocking the MDM2-p53 interaction represents an attrac...